Is gene therapy in cystic fibrosis a realistic expectation?

Current Opinion in Pulmonary Medicine

Volumn 2, Issue 6, 1996, Pages 466-471

  McElvaney, Noel G ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CFTR PROTEIN, HUMAN; COMPLEMENTARY DNA; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADENOVIRUS; CLINICAL PROTOCOL; CLINICAL TRIAL; CYSTIC FIBROSIS; FEASIBILITY STUDY; FORECASTING; FRANCE; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; LUNG; PNEUMONIA; REVIEW; SAFETY; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

ADENOVIRIDAE; CLINICAL PROTOCOLS; CLINICAL TRIALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA, COMPLEMENTARY; FEASIBILITY STUDIES; FORECASTING; FRANCE; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREAT BRITAIN; HUMANS; LUNG; PNEUMONIA; SAFETY; TREATMENT OUTCOME; UNITED STATES;

EID: 0030275760     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Rommens JM, Iannuzzi MC, Kerem B-S, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, et al.: Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245:1059-1065.
2. Riordan JR, Rommens JM, Kerem B-S, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou J-L, et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
3. Kerem B-S, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buckwald M, Tsui L-C: Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073-1080.
4. Boat TF, Welsh MJ, Beaudet AL: Cystic fibrosis. In The Metabolic Basis of Inherited Diseases edn 6. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 1989, 2649-2680.
5. FitzSimmons SC: The changing epidemiology of cystic fibrosis. J Pediatr 1993, 122:1-9.
6. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WR, Jolley CJ, Wu M, Chernick MS, Crystal RG: A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med 1992, 326:812-815.
7. Aitken ML, Burke W, McDonald G, Villalom M, Shak S, Montgomery AB, Smith AL: Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis: a phase I study. JAMA 1992, 267:1947-1951.
8. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME: Effect of aerosolized recombinant DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994, 331:637-642.
9. Konstan MW, Byard PJ, Hoppel CL, Davis PB: Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332:848-854.
10. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG: Aerosol α1-antitrypsin treatment for cystic fibrosis. Lancet 1991, 337:392-394.
11. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan PH, King M, Edwards LJ, Helms RW, Boucher RC: A pilot study of aerosolized amiloride for the treatment of cystic fibrosis lung disease. N Engl J Med 1990, 332:1189-1194.
12. Bear CE, Li C, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh M, Riordan JR: Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992, 68:809-818.
13. Stutts MJ, Canessa CM, Olsen JC, Hamrick M, Cohn JA, Rossier BC, Boucher RC: CFTR as a cAMP-dependent regulator of sodium channels. Science 1995, 269:847-850.
14. Gabriel SE, Clarke LL, Boucher RC, Slutts MJ: CFTR and outwardly rectifying chloride channels are distinct proteins with a regulatory relationship. Nature 1993, 363:263-266.
15. + secretion in nasal epithelia of CF mice. Am J Physiol 1994, 266:C1478-C1483.
16. Drumm M, Pope H, Cliff W, Rommens J, Marvin S, Tsui L, Collins F, Frizzell R, Wilson J: Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 1990, 62:1227-1233.
17. Rich DP, Anderson MP, Gregory RJ, Cheng SH, Paul S, Jefferson DM, McCann JD, Klinger KW, Smith Ae, Welsh MJ: Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990, 347:358-363.
18. Korst RJ, McElvaney NG, Chu C-S, Rosenfeld MA, Mastrangeli A, Hay J, Brody SL, Eissa NT, Danel C, Jaffe HA, Crystal RG: Gene therapy for the respiratory manifestations of cystic fibrosis. Am J Respir Crit Care Med 1995, 151:S75-S87.
19. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Pericaudet L, et al.: In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992, 68:143-155.
20. Yang Y, Li Q, Ertl HCJ, Wilson J: Cellular and humoral immune response to viral antigens create barriers to lung-directed therapy with recombinant adenoviruses. J Virol 1995, 69:2004-2015.
21. Brody SL, Metzger M, Danel C, Rosenfeld M, Crystal RG: Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther 1994, 5:821-836.
22. Yei S, Mittereder N, Wert S, Whitsett JA, Whilmott RW, Trapnell BC: In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther 1994, 5:731-744.
23. Crystal RG, McElvaney NG, Rosenfeld MA, Chu C-S, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994, 8:42-51. The first study detailing administration of an adenovirus vector containing the CFTR cDNA, showing evidence of efficacy and inflammation.
24. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ: Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993, 75:207-216.
25. Knowles MR, Hohneker K, Zhou ZQ, Olsen JC, Noah TL, Hu P-C, Leigh MW, Engelhardt JF, Edward LJ, Jones KR, et al.: A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995, 333:823-831. This study used an adenoviral vector system that showed no correction of functional defect in CF nasal epithelium despite molecular evidence of gene transfer. Lack of functional correction was perhaps explained by low percentage of epithelial cells transfected by vector.
26. Hay JG, McElvaney NG, Herena J, Crystal RG: Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 1995, 6:1487-1496. This study used a vector similar to that used by Knowles et al. (N Engl J Med, 1995, 333:823-831) but with a different delivery system. In contrast to the study by Knowles et al., this study showed some evidence of functional correction in CF nasal epithelium after vector administration.
27. Hay JG, McElvaney NG, Herena J, Crystal RG: Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 1995, 6:1487-1496. This study used a vector similar to that used by Knowles et al. (N Engl J Med, 1995, 333:823-831) but with a different delivery system. In contrast to the study by Knowles et al., this study showed some evidence of functional correction in CF nasal epithelium after vector administration.
28. - secretion, but there was less correction with subsequent administrations. This demonstrates two of the major barriers to adenoviral-mediated gene therapy, namely the need for repeat administration and the ability of the immune response to render repeat administration less effective.
29. Wickham TJ, Mathias P, Cheresh DA, Nemerov GR: Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment Cell 1993, 73:309-319.
30. Wilson JM: Gene therapy for cystic fibrosis: challenges and future directions. J Clin Invest 1995, 96:2547-2554.
31. Caplen NJ, Alton EWFW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffery PK, Hodson ME, Coutelle C, et al.: Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995, 1:39-46. The first published study of liposome-mediated transfer to the nasal epithelium of individuals with CF.
32. Sorscher EJ, Logan JJ, Frizzell RA, Lyrene RK, Bebok Z, Dong JY, Duvall MD, Felgner PL, Matalon S, Walker L, Wiatrak BJ: Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: a phase I trial of safety and efficacy in the nasal airway. Hum Gene Ther 1994, 5:1259-1277.
33. Podsakoff G, Wong KK Jr, Chatterjee S: Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 1994, 68:5656-5666.
34. Samulski RJ: Adeno-associated virus: integration at a specific chromosomal locus. Curr Opin Genet Dev 1993, 3:74-80.
35. Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, Zeitlin PL, Guggino WB, Carter BJ: Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A 1993, 90:10613-10617.
36. McElvaney NG, Crystal RG: IL6 release and air-way administration of human CFTR cDNA adenovirus vector. Nat Med 1995, 1:182-184. This study shows evidence for cytokine-based inflammatory response following administration of adenoviral vector.
37. Yang Y, Nunes F, Berensci K, Gonczol E, Engelhardt J, Wilson J: Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994, 7:362-369.
38. + cytotoxic T lymphocytes in vivo. J Immunol 1995, 155:2564-2570.
39. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 1994, 76:241-245.
40. Yang Y, Xiang Z, Ertl HCJ, Wilson JM: Upregulation of class I MHC antigens by interferon-g is necessary for the T cell-mediated elimination of recombinant adenovirus infected hepatocytes in vivo. Proc Natl Acad Sci U S A 1995, 92:7257-7261. This study details some of the ways in which the immune system can mediate clearance of adenoviral-infected cells.
41. Mitani K, Graham FL, Caskey CT, Kochanek S: Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A 1995, 92:3854-3858.
42. Wold W, Gooding L: Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology 1991, 184:1-8.
43. + T lymphocytes. Cell 1994, 77:525-535.
44. Jones TR, Hanson LK, Sun L, Slater JS, Stenberg RM, Campbell AE: Multiple indepenent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex I heavy chains. J Virol 1995, 69:4830-4841.
45. Yang Y, Trincheri G, Wilson JM: Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1995, 1:890-893.
46. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ: The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994, 15:406-411.
47. Bluestone JA: New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995, 2:555-559.
48. Mastrangeli A, Harvey B-G, Yao J, Wolff G, Kovesdi I, Crystal RG, Falck-Pedersen E: "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996, 7:79-87. Potential means by which the ability of antiadenovirus humoral immunity to prevent gene expression can be circumvented.